| |
original article |
Date |
Title |
Authors Max. 6 Authors |
| 1 |
[GO] |
2024―Aug―15 |
Nonpeptidic Irreversible Inhibitors of SARS-CoV-2 Main Protease with Potent Antiviral Activity |
Angelo Oneto, Ghazl Al Hamwi, Laura Schäkel, Nadine Krüger, Katharina Sylvester, Marvin Petry, Rasha Abu Shamleh, Thanigaimalai Pillaiyar, Tobias Claff, Anke C. Schiedel, Norbert Sträter, Michael Gütschow, Christa E. Müller |
| 2 |
[GO] |
2024―Aug―05 |
Non-Covalent Inhibitors of SARS-CoV-2 Papain-Like Protease (PLpro): In Vitro and In Vivo Antiviral Activity |
Ganga Reddy Velma, Zhengnan Shen, Cameron Holberg, Jiqiang Fu, Farinaz Soleymani, Laura Cooper, Omar Lozano Ramos, Divakar Indukuri, Soumya Reddy Musku, Pavel Rychetsky, Steve Slilaty, Zuomei Li, Kiira Ratia, Lijun Rong, Dominik Schenten, Rui Xiong, Gregory R. J Thatcher |
| 3 |
[GO] |
2024―Jul―12 |
Amphiphilic Heparinoids as Potent Antiviral Agents against SARS-CoV-2 |
Mohit Chhabra, Chethan D. Shanthamurthy, Nanjudaswamy Vijendra Kumar, Sandhya Mardhekar, Sharath S. Vishweshwara, Norbert Wimmer, Naphak Modhiran, Daniel Watterson, Alberto A. Amarilla, Jonathan S. Cha, James R. Beckett, James J. De Voss, Yasmin Kayal, Israel Vlodavsky, Lauren R. Dorsett, Raymond A. A. Smith, Neha S. Gandhi, Raghavendra Kikkeri, Vito Ferro |
| 4 |
[GO] |
2024―Jul―05 |
Fixing the Achilles Heel of Pfizer’s Paxlovid for COVID-19 Treatment |
Lennart Brewitz, Christopher J. Schofield |
| 5 |
[GO] |
2024―Jul―05 |
New Strategies for Responding to SARS-CoV-2: The Present and Future of Dual-Target Drugs |
Wenyi Zhang, Lecheng Xiao, Dianyang Li, Yuxuan Hu, Wenying Yu |
| 6 |
[GO] |
2024―Jul―02 |
Structure-Guided Design of Potent Coronavirus Inhibitors with a 2-Pyrrolidone Scaffold: Biochemical, Crystallographic, and Virological Studies |
Chamandi S. Dampalla, Yunjeong Kim, Alexandria Zabiegala, Dennis J. Howard, Harry Nhat Nguyen, Trent K. Madden, Hayden A. Thurman, Anne Cooper, Lijun Liu, Kevin P. Battaile, Scott Lovell, Kyeong-Ok Chang, William C. Groutas |
| 7 |
[GO] |
2024―Jun―14 |
Correction to “Discovery of CMX990: A Potent SARS-CoV-2 3CL Protease Inhibitor Bearing a Novel Warhead” |
N. G. R. Dayan Elshan, Karen C. Wolff, Laura Riva, Ashley K. Woods, Gennadii Grabovyi, Katy Wilson, James Pedroarena, Sourav Ghorai, Armen Nazarian, Frank Weiss, Yuyin Liu, Wrickban Mazumdar, Lirui Song, Neechi Okwor, Jacqueline Malvin, Dongdong Liu, Malina A. Bakowski, Nathan Beutler, Melanie G. Kirkpatrick, Amal Gebara-Lamb, Edward Huang, Vân T. B. Nguyen-Tran, Victor Chi, Shuangwei Li, Thomas F. Rogers, Case W. McNamara, Anil Kumar Gupta, Alireza Rahimi, Jian Jeffrey Chen, Sean B. Joseph, Peter G. Schultz, Arnab K. Chatterjee |
| 8 |
[GO] |
2024―Jun―12 |
Colloidal Aggregation Confounds Cell-Based Covid-19 Antiviral Screens |
Isabella S. Glenn, Lauren N. Hall, Mir M. Khalid, Melanie Ott, Brian K. Shoichet |
| 9 |
[GO] |
2024―May―30 |
Design, Synthesis, and Structure-Activity Relationships of Novel Peptide Derivatives of the Severe Acute Respiratory Syndrome-Coronavirus-2 Spike-Protein that Potently Inhibit Nicotinic Acetylcholine Receptors |
Arik J. Hone, Ulises Santiago, Peta J. Harvey, Bassel Tekarli, Joanna Gajewiak, David J. Craik, Carlos J. Camacho, J. Michael McIntosh |
| 10 |
[GO] |
2024―May―16 |
Macrocyclic Azapeptide Nitriles: Structure-Based Discovery of Potent SARS-CoV-2 Main Protease Inhibitors as Antiviral Drugs |
Julian Breidenbach, Rabea Voget, Yaoyao Si, Alexandra Hingst, Tobias Claff, Katharina Sylvester, Valentina Wolf, Vesa Krasniqi, Abibe Useini, Norbert Sträter, Yukino Ogura, Atsushi Kawaguchi, Christa E. Müller, Michael Gütschow |
| 11 |
[GO] |
2024―Apr―30 |
A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19 |
Charlotte M. N. Allerton, Joel T. Arcari, Lisa M. Aschenbrenner, Melissa Avery, Bruce M. Bechle, Mohammad Amin Behzadi, Britton Boras, Leanne M. Buzon, Rhonda D. Cardin, Natasha R. Catlin, Anthony A. Carlo, Karen J. Coffman, Alyssa Dantonio, Li Di, Heather Eng, Kathleen A. Farley, Rose Ann Ferre, Steven S. Gernhardt, Scott A. Gibson, Samantha E. Greasley, Siennah R. Greenfield, Brett L. Hurst, Amit S. Kalgutkar, Emi Kimito, Lorraine F. Lanyon, Gabrielle H. Lovett, Yajing Lian, Wei Liu, Luis A. Martínez Alsina, Stephen Noell, R. Scott Obach, Dafydd R. Owen, Nandini C. Patel, Devendra K. Rai, Matthew R. Reese, Hussin A. Rothan, Sylvie Sakata, Matthew F. Sammons, Jean G. Sathish, Raman Sharma, Claire M. Steppan, Jamison B. Tuttle, Patrick R. Verhoest, Liuqing Wei, Qingyi Yang, Irina Yurgelonis, Yuao Zhu |
| 12 |
[GO] |
2024―Apr―12 |
Discovery of First-in-Class PROTAC Degraders of SARS-CoV-2 Main Protease |
Yugendar R. Alugubelli, Jing Xiao, Kaustav Khatua, Sathish Kumar, Long Sun, Yuying Ma, Xinyu R. Ma, Veerabhadra R. Vulupala, Sandeep Atla, Lauren R. Blankenship, Demonta Coleman, Xuping Xie, Benjamin W. Neuman, Wenshe Ray Liu, Shiqing Xu |
| 13 |
[GO] |
2024―Apr―09 |
Discovery of 2-Amide-3-methylester Thiophenes that Target SARS-CoV-2 Mac1 and Repress Coronavirus Replication, Validating Mac1 as an Antiviral Target |
Sarah Wazir, Tomi A. O. Parviainen, Jessica J. Pfannenstiel, Men Thi Hoai Duong, Daniel Cluff, Sven T. Sowa, Albert Galera-Prat, Dana Ferraris, Mirko M. Maksimainen, Anthony R. Fehr, Juha P. Heiskanen, Lari Lehtiö |
| 14 |
[GO] |
2024―Feb―17 |
Invention of MK-7845, a SARS-CoV-2 3CL Protease Inhibitor Employing a Novel Difluorinated Glutamine Mimic |
Valerie W. Shurtleff, Mark E. Layton, Craig A. Parish, James J. Perkins, John D. Schreier, Yunyi Wang, Gregory C. Adam, Nadine Alvarez, Soheila Bahmanjah, Carolyn M. Bahnck-Teets, Christopher W. Boyce, Christine Burlein, Tamara D. Cabalu, Brian T. Campbell, Steven S. Carroll, Wonsuk Chang, Manuel de Lera Ruiz, Enriko Dolgov, John F. Fay, Nicholas G. Fox, Shih Lin Goh, Timothy J. Hartingh, Danielle M. Hurzy, Michael J. Kelly, Daniel J. Klein, Franca-Maria Klingler, Harini Krishnamurthy, Shalley Kudalkar, Todd W. Mayhood, Philip M. McKenna, Edward M. Murray, Debbie Nahas, Christopher C. Nawrat, Steven Park, Dongming Qian, Anthony J. Roecker, Vijeta Sharma, William D. Shipe, Jing Su, Robert V. Taggart, Quang Truong, Yin Wu, Xiaoyan Zhou, Ningning Zhuang, David S. Perlin, David B. Olsen, John A. Howe, John A. McCauley |
| 15 |
[GO] |
2024―Feb―09 |
Discovery of CMX990: A Potent SARS-CoV-2 3CL Protease Inhibitor Bearing a Novel Warhead |
N. G. R. Dayan Elshan, Karen C. Wolff, Laura Riva, Ashley K. Woods, Gennadii Grabovyi, Katy Wilson, James Pedroarena, Sourav Ghorai, Armen Nazarian, Frank Weiss, Yuyin Liu, Wrickban Mazumdar, Lirui Song, Neechi Okwor, Jacqueline Malvin, Malina A. Bakowski, Nathan Beutler, Melanie G. Kirkpatrick, Amal Gebara-Lamb, Edward Huang, Vân T. B. Nguyen-Tran, Victor Chi, Shuangwei Li, Thomas F. Rogers, Case W. McNamara, Anil Kumar Gupta, Alireza Rahimi, Jian Jeffrey Chen, Sean B. Joseph, Peter G. Schultz, Arnab K. Chatterjee |
| 16 |
[GO] |
2023―Nov―22 |
Design, Synthesis, and Biological Evaluation of Trisubstituted Piperazine Derivatives as Noncovalent Severe Acute Respiratory Syndrome Coronavirus 2 Main Protease Inhibitors with Improved Antiviral Activity and Favorable Druggability |
Shenghua Gao, Letian Song, Katharina Sylvester, Beatrice Mercorelli, Arianna Loregian, Karoly Toth, Renato H. Weiße, Abibe Useini, Norbert Sträter, Mianling Yang, Bing Ye, Ann E. Tollefson, Christa E. Müller, Xinyong Liu, Peng Zhan |
| 17 |
[GO] |
2023―Oct―30 |
Mapping the Lipid Signatures in COVID-19 Infection: Diagnostic and Therapeutic Solutions |
Aishi Dasgupta, Shon Gangai, Rishikesh Narayan, Shobhna Kapoor |
| 18 |
[GO] |
2023―Oct―26 |
Clinical Translation of Aptamers for COVID-19 |
Yang Zhang, Yongen Li |
| 19 |
[GO] |
2023―Sep―27 |
Structure-Activity Relationship Studies of SARS-CoV-2 Main Protease Inhibitors Containing 4-Fluorobenzothiazole-2-carbonyl Moieties |
Kohei Tsuji, Takahiro Ishii, Takuya Kobayakawa, Nobuyo Higashi-Kuwata, Kouki Shinohara, Chika Azuma, Yutaro Miura, Hiroki Nakano, Naoya Wada, Shin-ichiro Hattori, Haydar Bulut, Hiroaki Mitsuya, Hirokazu Tamamura |
| 20 |
[GO] |
2023―Aug―19 |
Discovery of GS-5245 (Obeldesivir), an Oral Prodrug of Nucleoside GS-441524 That Exhibits Antiviral Efficacy in SARS-CoV-2-Infected African Green Monkeys |
Richard L. Mackman, Rao V. Kalla, Darius Babusis, Jared Pitts, Kimberly T. Barrett, Kwon Chun, Venice Du Pont, Lauren Rodriguez, Jasmine Moshiri, Yili Xu, Michael Lee, Gary Lee, Blake Bleier, Anh-Quan Nguyen, B. Michael O’Keefe, Andrea Ambrosi, Meredith Cook, Joy Yu, Kassibla Elodie Dempah, Elaine Bunyan, Nicholas C. Riola, Xianghan Lu, Renmeng Liu, Ashley Davie, Tien-Ying Hsiang, Justin Dearing, Meghan Vermillion, Michael Gale, Anita Niedziela-Majka, Joy Y. Feng, Charlotte Hedskog, John P. Bilello, Raju Subramanian, Tomas Cihlar |
| 21 |
[GO] |
2023―Aug―18 |
Discovery and Mechanism Study of SARS-CoV-2 3C-like Protease Inhibitors with a New Reactive Group |
Pengxuan Ren, Hui Li, Tianqing Nie, Xiaoqin Jian, Changyue Yu, Jian Li, Haixia Su, Xianglei Zhang, Shiwei Li, Xin Yang, Chao Peng, Yue Yin, Leike Zhang, Yechun Xu, Hong Liu, Fang Bai |
| 22 |
[GO] |
2023―Aug―18 |
Alkyne as a Latent Warhead to Covalently Target SARS-CoV-2 Main Protease |
Chau Ngo, William Fried, Saba Aliyari, Joshua Feng, Chao Qin, Shilei Zhang, Hanjing Yang, Jean Shanaa, Pinghui Feng, Genhong Cheng, Xiaojiang S. Chen, Chao Zhang |
| 23 |
[GO] |
2023―Aug―10 |
A Systematic Survey of Reversibly Covalent Dipeptidyl Inhibitors of the SARS-CoV-2 Main Protease |
Zhi Zachary Geng, Sandeep Atla, Namir Shaabani, Veerabhadra Vulupala, Kai S. Yang, Yugendar R. Alugubelli, Kaustav Khatua, Peng-Hsun Chen, Jing Xiao, Lauren R. Blankenship, Xinyu R. Ma, Erol C. Vatansever, Chia-Chuan D. Cho, Yuying Ma, Robert Allen, Henry Ji, Shiqing Xu, Wenshe Ray Liu |
| 24 |
[GO] |
2023―Jul―20 |
C-2 Thiophenyl Tryptophan Trimers Inhibit Cellular Entry of SARS-CoV-2 through Interaction with the Viral Spike (S) Protein |
Marta Gargantilla, Clara Francés, Anmol Adhav, Alicia Forcada-Nadal, Belén Martínez-Gualda, Olaia Martí-Marí, María Luisa López-Redondo, Roberto Melero, Clara Marco-Marín, Nadine Gougeard, Carolina Espinosa, Antonio Rubio-del-Campo, Rafael Ruiz-Partida, María del Pilar Hernández-Sierra, Laura Villamayor-Belinchón, Jerónimo Bravo, José-Luis Llacer, Alberto Marina, Vicente Rubio, Ana San-Félix, Ron Geller, María-Jesús Pérez-Pérez |
| 25 |
[GO] |
2023―Jun―09 |
Structure-Based Discovery of Inhibitors of the SARS-CoV-2 Nsp14 N7-Methyltransferase |
Isha Singh, Fengling Li, Elissa A. Fink, Irene Chau, Alice Li, Annía Rodriguez-Hernández, Isabella Glenn, Francisco J. Zapatero-Belinchón, M. Luis Rodriguez, Kanchan Devkota, Zhijie Deng, Kris White, Xiaobo Wan, Nataliya A. Tolmachova, Yurii S. Moroz, H. Ümit Kaniskan, Melanie Ott, Adolfo García-Sastre, Jian Jin, Danica Galonić Fujimori, John J. Irwin, Masoud Vedadi, Brian K. Shoichet |
| 26 |
[GO] |
2023―Apr―11 |
1-O-Octadecyl-2-O-benzyl-sn-glyceryl-3-phospho-GS-441524 (V2043). Evaluation of Oral V2043 in a Mouse Model of SARS-CoV-2 Infection and Synthesis and Antiviral Evaluation of Additional Phospholipid Esters with Enhanced Anti-SARS-CoV-2 Activity |
Aaron F. Carlin, James R. Beadle, Alex E. Clark, Kendra L. Gully, Fernando R. Moreira, Ralph S. Baric, Rachel L. Graham, Nadejda Valiaeva, Sandra L. Leibel, William Bray, Rachel E. McMillan, Jonathan E. Freshman, Aaron F. Garretson, Rachael N. McVicar, Tariq Rana, Xing-Quan Zhang, Joyce A. Murphy, Robert T. Schooley, Karl Y. Hostetler |
| 27 |
[GO] |
2023―Feb―09 |
Alkyne Derivatives of SARS-CoV-2 Main Protease Inhibitors Including Nirmatrelvir Inhibit by Reacting Covalently with the Nucleophilic Cysteine |
Lennart Brewitz, Leo Dumjahn, Yilin Zhao, C. David Owen, Stephen M. Laidlaw, Tika R. Malla, Dung Nguyen, Petra Lukacik, Eidarus Salah, Adam D. Crawshaw, Anna J. Warren, Jose Trincao, Claire Strain-Damerell, Miles W. Carroll, Martin A. Walsh, Christopher J. Schofield |
| 28 |
[GO] |
2023―Jan―10 |
Self-Adjuvanting Protein Vaccine Conjugated with a Novel Synthetic TLR4 Agonist on Virus-Like Liposome Induces Potent Immunity against SARS-CoV-2 |
Dong Ding, Yu Wen, Chun-Miao Liao, Xu-Guang Yin, Ru-Yan Zhang, Jian Wang, Shi-Hao Zhou, Zhi-Ming Zhang, Yong-Ke Zou, Xiao-Fei Gao, Hua-Wei Wei, Guang-Fu Yang, Jun Guo |
| 29 |
[GO] |
2022―Dec―12 |
Structure-Based Design of a Dual-Targeted Covalent Inhibitor Against Papain-like and Main Proteases of SARS-CoV-2 |
Wenying Yu, Yucheng Zhao, Hui Ye, Nanping Wu, Yixian Liao, Nannan Chen, Zhiling Li, Ning Wan, Haiping Hao, Honggao Yan, Yibei Xiao, Maode Lai |
| 30 |
[GO] |
2022―Dec―07 |
Discovery and Crystallographic Studies of Nonpeptidic Piperazine Derivatives as Covalent SARS-CoV-2 Main Protease Inhibitors |
Shenghua Gao, Letian Song, Tobias Claff, Molly Woodson, Katharina Sylvester, Lanlan Jing, Renato H. Weiße, Yusen Cheng, Norbert Sträter, Laura Schäkel, Michael Gütschow, Bing Ye, Mianling Yang, Tao Zhang, Dongwei Kang, Karoly Toth, John Tavis, Ann E. Tollefson, Christa E. Müller, Peng Zhan, Xinyong Liu |
| 31 |
[GO] |
2022―Nov―10 |
Two Binding Sites of SARS-CoV-2 Macrodomain 3 Probed by Oxaprozin and Meclomen |
Jiao Li, Fumei Zhong, Mingwei Li, Yaqian Liu, Lei Wang, Mingqing Liu, Fudong Li, Jiahai Zhang, Jihui Wu, Yunyu Shi, Zhiyong Zhang, Xiaoming Tu, Ke Ruan, Jia Gao |
| 32 |
[GO] |
2022―Oct―14 |
Discovery of Chlorofluoroacetamide-Based Covalent Inhibitors for Severe Acute Respiratory Syndrome Coronavirus 2 3CL Protease |
Yuya Hirose, Naoya Shindo, Makiko Mori, Satsuki Onitsuka, Hikaru Isogai, Rui Hamada, Tadanari Hiramoto, Jinta Ochi, Daisuke Takahashi, Tadashi Ueda, Jose M. M. Caaveiro, Yuya Yoshida, Shigehiro Ohdo, Naoya Matsunaga, Shinsuke Toba, Michihito Sasaki, Yasuko Orba, Hirofumi Sawa, Akihiko Sato, Eiji Kawanishi, Akio Ojida |
| 33 |
[GO] |
2022―Sep―30 |
Diastereomeric Resolution Yields Highly Potent Inhibitor of SARS-CoV-2 Main Protease |
Mark S. Cooper, Linlin Zhang, Mohamed Ibrahim, Kaixuan Zhang, Xinyuanyuan Sun, Judith Röske, Matthias Göhl, Mark Brönstrup, Justin K. Cowell, Lucie Sauerhering, Stephan Becker, Laura Vangeel, Dirk Jochmans, Johan Neyts, Katharina Rox, Graham P. Marsh, Hannah J. Maple, Rolf Hilgenfeld |
| 34 |
[GO] |
2022―Sep―28 |
Targeting SARS-CoV-2 Main Protease for Treatment of COVID-19: Covalent Inhibitors Structure-Activity Relationship Insights and Evolution Perspectives |
Gabriele La Monica, Alessia Bono, Antonino Lauria, Annamaria Martorana |
| 35 |
[GO] |
2022―Sep―15 |
Discovery and Crystallographic Studies of Trisubstituted Piperazine Derivatives as Non-Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity and Low Toxicity |
Shenghua Gao, Katharina Sylvester, Letian Song, Tobias Claff, Lanlan Jing, Molly Woodson, Renato H. Weiße, Yusen Cheng, Laura Schäkel, Marvin Petry, Michael Gütschow, Anke C. Schiedel, Norbert Sträter, Dongwei Kang, Shujing Xu, Karoly Toth, John Tavis, Ann E. Tollefson, Christa E. Müller, Xinyong Liu, Peng Zhan |
| 36 |
[GO] |
2022―Jun―22 |
Evolutionary and Structural Insights about Potential SARS-CoV-2 Evasion of Nirmatrelvir |
Kai S. Yang, Sunshine Z. Leeuwon, Shiqing Xu, Wenshe Ray Liu |
| 37 |
[GO] |
2022―Jun―16 |
Small-Molecule Thioesters as SARS-CoV-2 Main Protease Inhibitors: Enzyme Inhibition, Structure-Activity Relationships, Antiviral Activity, and X-ray Structure Determination |
Thanigaimalai Pillaiyar, Philipp Flury, Nadine Krüger, Haixia Su, Laura Schäkel, Elany Barbosa Da Silva, Olga Eppler, Thales Kronenberger, Tianqing Nie, Stephanie Luedtke, Cheila Rocha, Katharina Sylvester, Marvin R.I. Petry, James H. McKerrow, Antti Poso, Stefan Pöhlmann, Michael Gütschow, Anthony J. O’Donoghue, Yechun Xu, Christa E. Müller, Stefan A. Laufer |
| 38 |
[GO] |
2022―May―31 |
Structure-Guided Design of Potent Spirocyclic Inhibitors of Severe Acute Respiratory Syndrome Coronavirus-2 3C-like Protease |
Chamandi S. Dampalla, Athri D. Rathnayake, Anushka C. Galasiti Kankanamalage, Yunjeong Kim, Krishani Dinali Perera, Harry Nhat Nguyen, Matthew J. Miller, Trent K. Madden, Hunter R. Picard, Hayden A. Thurman, Maithri M. Kashipathy, Lijun Liu, Kevin P. Battaile, Scott Lovell, Kyeong-Ok Chang, William C. Groutas |
| 39 |
[GO] |
2022―May―27 |
Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease |
Haozhou Tan, Yanmei Hu, Prakash Jadhav, Bin Tan, Jun Wang |
| 40 |
[GO] |
2022―May―12 |
Penicillin Derivatives Inhibit the SARS-CoV-2 Main Protease by Reaction with Its Nucleophilic Cysteine |
Tika R. Malla, Lennart Brewitz, Dorian-Gabriel Muntean, Hiba Aslam, C. David Owen, Eidarus Salah, Anthony Tumber, Petra Lukacik, Claire Strain-Damerell, Halina Mikolajek, Martin A. Walsh, Christopher J. Schofield |
| 41 |
[GO] |
2022―May―04 |
S-217622, a 3CL Protease Inhibitor and Clinical Candidate for SARS-CoV-2 |
Joel D. A. Tyndall |
| 42 |
[GO] |
2022―Apr―19 |
Potent Inhibition of SARS-CoV-2 nsp14 N7-Methyltransferase by Sulfonamide-Based Bisubstrate Analogues |
Rostom Ahmed-Belkacem, Marcel Hausdorff, Adrien Delpal, Priscila Sutto-Ortiz, Agathe M. G. Colmant, Franck Touret, Natacha S. Ogando, Eric J. Snijder, Bruno Canard, Bruno Coutard, Jean-Jacques Vasseur, Etienne Decroly, Françoise Debart |
| 43 |
[GO] |
2022―Mar―30 |
Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19 |
Yuto Unoh, Shota Uehara, Kenji Nakahara, Haruaki Nobori, Yukiko Yamatsu, Shiho Yamamoto, Yuki Maruyama, Yoshiyuki Taoda, Koji Kasamatsu, Takahiro Suto, Kensuke Kouki, Atsufumi Nakahashi, Sho Kawashima, Takao Sanaki, Shinsuke Toba, Kentaro Uemura, Tohru Mizutare, Shigeru Ando, Michihito Sasaki, Yasuko Orba, Hirofumi Sawa, Akihiko Sato, Takafumi Sato, Teruhisa Kato, Yuki Tachibana |
| 44 |
[GO] |
2022―Feb―09 |
Advances Toward COVID-19 Therapies Special Issue |
Nouri Neamati |
| 45 |
[GO] |
2022―Feb―02 |
MPLA-Adjuvanted Liposomes Encapsulating S-Trimer or RBD or S1, but Not S-ECD, Elicit Robust Neutralization Against SARS-CoV-2 and Variants of Concern |
Jian Wang, Xu-Guang Yin, Yu Wen, Jie Lu, Ru-Yan Zhang, Shi-Hao Zhou, Chun-Miao Liao, Hua-Wei Wei, Jun Guo |
| 46 |
[GO] |
2022―Jan―24 |
Self-Adjuvanting Lipoprotein Conjugate αGalCer-RBD Induces Potent Immunity against SARS-CoV-2 and its Variants of Concern |
Jian Wang, Yu Wen, Shi-Hao Zhou, Hai-Wei Zhang, Xiao-Qian Peng, Ru-Yan Zhang, Xu-Guang Yin, Hong Qiu, Rui Gong, Guang-Fu Yang, Jun Guo |
| 47 |
[GO] |
2022―Jan―04 |
Design and Evaluation of a Novel Peptide-Drug Conjugate Covalently Targeting SARS-CoV-2 Papain-like Protease |
Na Liu, Yichi Zhang, Yingshou Lei, Rui Wang, Meimiao Zhan, Jianbo Liu, Yuhao An, Yaoqi Zhou, Jian Zhan, Feng Yin, Zigang Li |
| 48 |
[GO] |
2021―Dec―05 |
Structure-Guided Design of Potent Inhibitors of SARS-CoV-2 3CL Protease: Structural, Biochemical, and Cell-Based Studies |
Chamandi S. Dampalla, Athri D. Rathnayake, Krishani Dinali Perera, Abdul-Rahman M. Jesri, Harry Nhat Nguyen, Matthew J. Miller, Hayden A. Thurman, Jian Zheng, Maithri M. Kashipathy, Kevin P. Battaile, Scott Lovell, Stanley Perlman, Yunjeong Kim, William C. Groutas, Kyeong-Ok Chang |
| 49 |
[GO] |
2021―Nov―24 |
Stapled Peptides Targeting SARS-CoV-2 Spike Protein HR1 Inhibit the Fusion of Virus to Its Cell Receptor |
Mengjun Zheng, Wei Cong, Haoran Peng, Jie Qing, Huaxing Shen, Yaxin Tang, Chenchen Geng, Si Chen, Yan Zou, Wei-Dong Zhang, Hong-Gang Hu, Xiang Li |
| 50 |
[GO] |
2021―Nov―23 |
Colloidal Aggregators in Biochemical SARS-CoV-2 Repurposing Screens |
Henry R. O’Donnell, Tia A. Tummino, Conner Bardine, Charles S. Craik, Brian K. Shoichet |
| 51 |
[GO] |
2021―Nov―20 |
Perspectives on SARS-CoV-2 Main Protease Inhibitors |
Kaifu Gao, Rui Wang, Jiahui Chen, Jetze J. Tepe, Faqing Huang, Guo-Wei Wei |
| 52 |
[GO] |
2021―Oct―27 |
Structural, Electronic, and Electrostatic Determinants for Inhibitor Binding to Subsites S1 and S2 in SARS-CoV-2 Main Protease |
Daniel W. Kneller, Hui Li, Stephanie Galanie, Gwyndalyn Phillips, Audrey Labbé, Kevin L. Weiss, Qiu Zhang, Mark A. Arnould, Austin Clyde, Heng Ma, Arvind Ramanathan, Colleen B. Jonsson, Martha S. Head, Leighton Coates, John M. Louis, Peter V. Bonnesen, Andrey Kovalevsky |
| 53 |
[GO] |
2021―Oct―21 |
Design of SARS-CoV-2 PLpro Inhibitors for COVID-19 Antiviral Therapy Leveraging Binding Cooperativity |
Zhengnan Shen, Kiira Ratia, Laura Cooper, Deyu Kong, Hyun Lee, Youngjin Kwon, Yangfeng Li, Saad Alqarni, Fei Huang, Oleksii Dubrovskyi, Lijun Rong, Gregory R. J. Thatcher, Rui Xiong |
| 54 |
[GO] |
2021―Oct―09 |
Computational Design of Potent D-Peptide Inhibitors of SARS-CoV-2 |
Pedro A. Valiente, Han Wen, Satra Nim, JinAh Lee, Hyeon Ju Kim, Jinhee Kim, Albert Perez-Riba, Yagya Prasad Paudel, Insu Hwang, Kyun-Do Kim, Seungtaek Kim, Philip M. Kim |
| 55 |
[GO] |
2021―Sep―27 |
Discovery and Mechanism of SARS-CoV-2 Main Protease Inhibitors |
Sarah Huff, Indrasena Reddy Kummetha, Shashi Kant Tiwari, Matthew B. Huante, Alex E. Clark, Shaobo Wang, William Bray, Davey Smith, Aaron F. Carlin, Mark Endsley, Tariq M. Rana |
| 56 |
[GO] |
2021―Sep―17 |
Synthetic Neutralizing Peptides Inhibit the Host Cell Binding of Spike Protein and Block Infection of SARS-CoV-2 |
Tao Wang, Xiaocui Fang, Tao Wen, Jian Liu, Zhaoyi Zhai, Zhiyou Wang, Jie Meng, Yanlian Yang, Chen Wang, Haiyan Xu |
| 57 |
[GO] |
2021―Sep―16 |
Indole Chloropyridinyl Ester-Derived SARS-CoV-2 3CLpro Inhibitors: Enzyme Inhibition, Antiviral Efficacy, Structure-Activity Relationship, and X-ray Structural Studies |
Arun K. Ghosh, Jakka Raghavaiah, Dana Shahabi, Monika Yadav, Brandon J. Anson, Emma K. Lendy, Shin-ichiro Hattori, Nobuyo Higashi-Kuwata, Hiroaki Mitsuya, Andrew D. Mesecar |
| 58 |
[GO] |
2021―Aug―04 |
Structure-Based Optimization of ML300-Derived, Noncovalent Inhibitors Targeting the Severe Acute Respiratory Syndrome Coronavirus 3CL Protease (SARS-CoV-2 3CLpro) |
Sang Hoon Han, Christopher M. Goins, Tarun Arya, Woo-Jin Shin, Joshua Maw, Alice Hooper, Dhiraj P. Sonawane, Matthew R. Porter, Breyanne E. Bannister, Rachel D. Crouch, A. Abigail Lindsey, Gabriella Lakatos, Steven R. Martinez, Joseph Alvarado, Wendell S. Akers, Nancy S. Wang, Jae U. Jung, Jonathan D. Macdonald, Shaun R. Stauffer |
| 59 |
[GO] |
2021―Jul―30 |
Synthetic Peptides That Antagonize the Angiotensin-Converting Enzyme-2 (ACE-2) Interaction with SARS-CoV-2 Receptor Binding Spike Protein |
Afsaneh Sadremomtaz, Zayana M. Al-Dahmani, Angel J. Ruiz-Moreno, Alessandra Monti, Chao Wang, Taha Azad, John C. Bell, Nunzianna Doti, Marco A. Velasco-Velázquez, Debora de Jong, Jørgen de Jonge, Jolanda Smit, Alexander Dömling, Harry van Goor, Matthew R. Groves |
| 60 |
[GO] |
2021―Jul―19 |
Potent Neutralizing Antibodies Elicited by RBD-Fc-Based COVID-19 Vaccine Candidate Adjuvanted by the Th2-Skewing iNKT Cell Agonist |
Xi-Feng Wang, Meng-Jia Zhang, Na He, Ya-Cong Wang, Cheng Yan, Xiang-Zhao Chen, Xiao-Fei Gao, Jun Guo, Rui Luo, Zheng Liu |
| 61 |
[GO] |
2021―Jul―09 |
Peptidomimetic α-Acyloxymethylketone Warheads with Six-Membered Lactam P1 Glutamine Mimic: SARS-CoV-2 3CL Protease Inhibition, Coronavirus Antiviral Activity, and in Vitro Biological Stability |
Bing Bai, Alexandr Belovodskiy, Mostofa Hena, Appan Srinivas Kandadai, Michael A. Joyce, Holly A. Saffran, Justin A. Shields, Muhammad Bashir Khan, Elena Arutyunova, Jimmy Lu, Sardeev K. Bajwa, Darren Hockman, Conrad Fischer, Tess Lamer, Wayne Vuong, Marco J. van Belkum, Zhengxian Gu, Fusen Lin, Yanhua Du, Jia Xu, Mohammad Rahim, Howard S. Young, John C. Vederas, D. Lorne Tyrrell, M. Joanne Lemieux, James A. Nieman |
| 62 |
[GO] |
2021―Jul―02 |
Structure-Guided Design of Conformationally Constrained Cyclohexane Inhibitors of Severe Acute Respiratory Syndrome Coronavirus-2 3CL Protease |
Chamandi S. Dampalla, Yunjeong Kim, Naemi Bickmeier, Athri D. Rathnayake, Harry Nhat Nguyen, Jian Zheng, Maithri M. Kashipathy, Matthew A. Baird, Kevin P. Battaile, Scott Lovell, Stanley Perlman, Kyeong-Ok Chang, William C. Groutas |
| 63 |
[GO] |
2021―Apr―23 |
Expedited Approach toward the Rational Design of Noncovalent SARS-CoV-2 Main Protease Inhibitors |
Naoya Kitamura, Michael Dominic Sacco, Chunlong Ma, Yanmei Hu, Julia Alma Townsend, Xiangzhi Meng, Fushun Zhang, Xiujun Zhang, Mandy Ba, Tommy Szeto, Adis Kukuljac, Michael Thomas Marty, David Schultz, Sara Cherry, Yan Xiang, Yu Chen, Jun Wang |
| 64 |
[GO] |
2021―Apr―22 |
Betulonic Acid Derivatives Interfering with Human Coronavirus 229E Replication via the nsp15 Endoribonuclease |
Annelies Stevaert, Besir Krasniqi, Benjamin Van Loy, Tien Nguyen, Joice Thomas, Julie Vandeput, Dirk Jochmans, Volker Thiel, Ronald Dijkman, Wim Dehaen, Arnout Voet, Lieve Naesens |
| 65 |
[GO] |
2021―Apr―19 |
Design, Synthesis, and Biological Evaluation of Peptidomimetic Aldehydes as Broad-Spectrum Inhibitors against Enterovirus and SARS-CoV-2 |
Wenhao Dai, Dirk Jochmans, Hang Xie, Hang Yang, Jian Li, Haixia Su, Di Chang, Jiang Wang, Jingjing Peng, Lili Zhu, Yong Nian, Rolf Hilgenfeld, Hualiang Jiang, Kaixian Chen, Leike Zhang, Yechun Xu, Johan Neyts, Hong Liu |
| 66 |
[GO] |
2021―Apr―15 |
Insights into SARS-CoV-2’s Mutations for Evading Human Antibodies: Sacrifice and Survival |
Binquan Luan, Tien Huynh |
| 67 |
[GO] |
2021―Mar―23 |
Direct Observation of Protonation State Modulation in SARS-CoV-2 Main Protease upon Inhibitor Binding with Neutron Crystallography |
Daniel W. Kneller, Gwyndalyn Phillips, Kevin L. Weiss, Qiu Zhang, Leighton Coates, Andrey Kovalevsky |
| 68 |
[GO] |
2021―Feb―03 |
Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mouse Models |
Yingjun Li, Liu Cao, Ge Li, Feng Cong, Yunfeng Li, Jing Sun, Yinzhu Luo, Guijiang Chen, Guanguan Li, Ping Wang, Fan Xing, Yanxi Ji, Jincun Zhao, Yu Zhang, Deyin Guo, Xumu Zhang |
| 69 |
[GO] |
2020―Dec―02 |
Advances toward COVID-19 Therapies Special Issue Call for Papers |
Hong Liu, Nouri Neamati, Nicholas Meanwell, Wendy Young, Gunda I. Georg, Shaomeng Wang |
| 70 |
[GO] |
2020―Nov―13 |
Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities |
Rolando Cannalire, Carmen Cerchia, Andrea R. Beccari, Francesco Saverio Di Leva, Vincenzo Summa |
| 71 |
[GO] |
2020―Oct―15 |
Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19 |
Robert L. Hoffman, Robert S. Kania, Mary A. Brothers, Jay F. Davies, Rose A. Ferre, Ketan S. Gajiwala, Mingying He, Robert J. Hogan, Kirk Kozminski, Lilian Y. Li, Jonathan W. Lockner, Jihong Lou, Michelle T. Marra, Lennert J. Mitchell, Brion W. Murray, James A. Nieman, Stephen Noell, Simon P. Planken, Thomas Rowe, Kevin Ryan, George J. Smith, James E. Solowiej, Claire M. Steppan, Barbara Taggart |
| 72 |
[GO] |
2020―Aug―26 |
Chinese therapeutic strategy for fighting COVID-19 and potential small-molecule inhibitors against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
Namrta Choudhry, Xin Zhao, Dan Xu, Mark Zanin, Weisan Chen, Zi-Feng Yang, Jianxin Chen |
| 73 |
[GO] |
2020―Jul―21 |
Lung protection by cathepsin C inhibition: a new hope for COVID-19 and ARDS? |
Brice Korkmaz, Adam Lesner, sylvain marchand-adam, Celia Moss, Dieter Erich Jenne |
| 74 |
[GO] |
2020―Jun―15 |
Inhibitors of SARS-CoV-2 Entry: Current and Future Opportunities |
Siyu Xiu, alexej dick, Han Ju, Sako Mirzaie, Fatemeh Abdi, Simon Cocklin, Peng Zhan, Xinyong Liu |
| 75 |
[GO] |
2020―Jun―08 |
COVID-19: Drug targets and potential treatments |
Carmen Gil, Tiziana Ginex, Ines Maestro, Vanesa Nozal, Lucia Barrado-Gil, Miguel A. Cuesta-Geijo, Jesus Urquiza, David Ramírez, Covadonga Alonso, Nuria E. Campillo, Ana Martínez |
| 76 |
[GO] |
2020―Feb―27 |
Structure-based stabilization of non-native protein-protein interactions of coronavirus nucleocapsid proteins in antiviral drug design |
Shan-Meng Lin, Shih-Chao Lin, Jia-Ning Hsu, Chung-ke Chang, Ching-Ming Chien, Yong-Sheng Wang, Hung-Yi Wu, U-Ser Jeng, Kylene Kehn-Hall, Ming-hon Hou |
| 77 |
[GO] |
2020―Feb―11 |
Alpha-ketoamides as broad-spectrum inhibitors of coronavirus and enterovirus replication Structure-based design, synthesis, and activity assessment |
Linlin Zhang, Daizong Lin, Yuri Kusov, Yong Nian, Qingjun Ma, Jiang Wang, Albrecht von Brunn, Pieter LEYSSEN, Kristina Lanko, Johan Neyts, Adriaan H. de Wilde, Eric J. Snijder, Hong Liu, Rolf Hilgenfeld |
|
